ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV Dolutegravir is the first ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

The US Food and Drug Administration (FDA) has approved the first dispersible tablet formulation of dolutegravir (Tivicay PD, ViiV Healthcare) to treat HIV-1 infection in children at least 4 weeks old ...

* VIIV HEALTHCARE -TIVICAY PD, EXTENDED INDICATION OF EXISTING TIVICAY 50MG FILM-COATED TABLET ARE CURRENTLY UNDER REVIEW BY EUROPEAN MEDICINES AGENCY * VIIV HEALTHCARE - DOLUTEGRAVIR IS 1ST INTEGRASE ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the US Food ...